Rethinking the appraisal and approval of drugs for type 2 diabetes
Naci, H.
, Lehman, R., Wouters, O. J., Goldacre, B. & Yudkin, J. S.
(2015).
Rethinking the appraisal and approval of drugs for type 2 diabetes.
BMJ,
351(h5260).
https://doi.org/10.1136/bmj.h5260
, Lehman, R., Wouters, O. J., Goldacre, B. & Yudkin, J. S.
(2015).
Rethinking the appraisal and approval of drugs for type 2 diabetes.
BMJ,
351(h5260).
https://doi.org/10.1136/bmj.h5260
The process for approving new drugs for type 2 diabetes illustrates the significant shortcomings of the regulatory standards for licensing, reimbursing, and adopting new drugs. Regulatory reform is needed to improve the real-world therapeutic value of anti-diabetic drugs.